Back to search

Article

Transcriptome and Metabolome based candidate mechanism of BCR-ABL independent resistance to Olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

2022-12-28

Abstract excerpt

Olverembatinib represents the third-generation breakpoint cluster region protein-Abelson-murine leukemia 1 (BCR-ABL1) tyrosine kinase inhibitor (TKI) with oral bioavailability, which can be used to overcome the T315I mutation in Philadelphia chromosome-positive (Ph+) leukemia. BCR-ABL independent resistance to Olverembatinib has been reported among patients in various clinical cases. However, the mechanism of Olve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
64192a86-bc07-5810-8ea1-6972d3297441
DOI
10.21203/rs.3.rs-2402198/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Transcriptome and Metabolome based candidate mechanism of BCR-ABL independent resistance to Olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemiaDOI 10.21203/rs.3.rs-2402198/v1
Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Semantic proximity
Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Semantic proximity
Pharmacogenomics in acute myeloid leukemia.Semantic proximity
Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A reviewSemantic proximity
Unveiling the omics tapestry of B-acute lymphoblastic leukemia: bridging genomics, metabolomics, and immunomicsSemantic proximity
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity
Resistant mutations in CML and Ph+ALL – role of ponatinibSemantic proximity
Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage—Similarities and Differences with the Myeloid Lineage and Specific VulnerabilitiesSemantic proximity
Ponatinib in refractory Philadelphia chromosome-positive leukemias.Semantic proximity
Proteomic profiling reveals pleiotropic antimetabolite activity of triciribine in acute lymphoblastic leukemiaSemantic proximity
Multi-omics data integration reveals molecular mechanisms of carfilzomib resistance in multiple myelomaSemantic proximity
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity
Select a neighboring publication to make it the new centre.